Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared on X:
“FDA-cleared PE AI, real world vs clearance (Nature Portfolio npj Digit Med, 17 sites)
- CTPA sensitivity 86.8% vs 94.9% in 510(k)
- Incidental PE 73.5% vs 89.7%
- Subsegmental 72.9%; non-acute 65.3%
Who should check AI tools after go-live, and how often?”
You can also read:
Douglas Flora: How Can AI Transform Cancer Care Without Losing the Human Touch?
